Dexcom G6 users can see glucose levels and trends at a glance, even while working out.
Partners offer app compatibility with Tempo Pen and Tempo Smart Button to help streamline diabetes management.
The two companies will collaborate to create a new version of the BlueStar insulin management solution that integrates insulin data for Lilly insulins.
This year, it is expected to exceed $742M, growing at an average CAGR of 50% annually.
The device uses thermographic monitoring of a patient's feet to identify early onset of diabetic foot ulcers, which can lead to limb loss if not detected early.
The partnership will provide personalized diabetes support with the protection of life insurance and the potential to earn up to 25% in premium savings.
The collaboration combines Abbott′s glucose sensing technology with Omada Health's proprietary digital coaching platform to provide personalized care.
The contract will cover eligible members who are living with Type 1 or Type 2 diabetes, covering 5.3 million federal employees, retirees and their families.
The company's implantable system is the only long-term CGM that lasts up to 90 days; it is now available for $99 plus the cost of the sensor placement.
The diabetes risk was calculated from the analysis of data 23andMe collected from more than 2.5 million customers who opted in to its research.